首页> 美国卫生研究院文献>International Journal of Endocrinology and Metabolism >A Novel Medical Treatment of Cushings Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1
【2h】

A Novel Medical Treatment of Cushings Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1

机译:新型药物治疗1型神经纤维瘤病患者因异位ACTH引起的库欣病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 64-year-old male presented with neurofibromatosis 1 and Cushing’s syndrome. Clinically he was over weight, depressed with extensive skin bruising and hypertension. His 24 hours urinary metanephrines, urinary 5HIAA, gut peptides and chromgranin levels were normal. His renal function and renal MRI scan was also normal. His cortisol failed to suppress on overnight dexamethsone suppression test. His low dose dexamethasone suppression with CRH stimulation showed failure of suppression of cortisol to < 50 nmol/L and ACTH was measurable at 10 ng/L on day 3. There was no response of ACTH or cortisol to CRH stimulation. His ACTH precursors were high at 126 pmol/L consistent with defective pro-opiomelanocortin (POMC) processing suggesting an ectopic source of ACTH production. The MRI scan of his pituitary and CT scan of the adrenal glands was normal. His octreotide scan was negative. The source of his ectopic ACTH was most likely a large retroperitoneal plexiform neurofibroma seen on CT abdomen that had undergone malignant peripheral nerve sheath tumour transformation on histology. He was a poor surgical risk for tumour debulking procedure. In view of the available literature and role of c-kit signalling in neurofibromatosis, he was treated with Imitinib. Four months after the treatment his Cushings had resolved on biochemical testing. After a year his plexiform neurofibroma has not increased in size. To our knowledge, this is the first case of NF1 associated with clinical and biochemical features of Cushing’s secondary to ectopic ACTH due to MPNST in a plexiform neurofibroma and its resolution on treatment with imatinib.
机译:一名64岁的男性,患有神经纤维瘤病1和库欣综合征。临床上,他体重超重,因广泛的皮肤淤青和高血压而沮丧。他的24小时尿中肾上腺素,尿5HIAA,肠肽和嗜铬粒蛋白水平正常。他的肾功能和肾脏MRI扫描也正常。在过夜地塞米松抑制试验中,他的皮质醇未能抑制。他的CRH刺激低剂量地塞米松抑制作用显示,皮质醇抑制至<50 nmol / L失败,并且在第3天可测量10 ng / L的ACTH。ACTH或氢化可的松对CRH刺激无反应。他的促肾上腺皮质激素前体高至126 pmol / L,这与有缺陷的前opiomelanocortin(POMC)加工相一致,表明了促肾上腺皮质激素产生的异位来源。垂体的MRI扫描和肾上腺的CT扫描正常。他的奥曲肽扫描呈阴性。他的异位促肾上腺皮质激素的来源很可能是CT腹部见到的大型腹膜后丛状神经纤维瘤,其组织学已经历了恶性周围神经鞘瘤的转化。对于肿瘤减灭术,他的手术风险很低。鉴于现有文献和c-kit信号在神经纤维瘤病中的作用,他接受了伊米替尼治疗。治疗四个月后,他的库欣(Cushings)接受了生化测试。一年后,他的丛状神经纤维瘤的大小没有增加。据我们所知,这是第一例神经丛神经纤维瘤中MPNST引起的库欣继发于异位ACTH的临床和生化特征相关的NF1病例,并通过伊马替尼治疗得以解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号